Witnessing An Insider Decision, John L Higgins Exercises Options Valued At $310K At Bio-Techne

A significant insider transaction involving the exercise of company stock options was reported on September 16, by John L Higgins, Director at Bio-Techne TECH, as per the latest SEC filing.

What Happened: A notable Form 4 filing on Monday with the U.S. Securities and Exchange Commission revealed that Higgins, Director at Bio-Techne, exercised stock options for 6,000 shares of TECH, resulting in a transaction value of $310,860.

Bio-Techne shares are trading down 0.0% at $74.76 at the time of this writing on Tuesday morning. Since the current price is $74.76, this makes Higgins's 6,000 shares worth $310,860.

Delving into Bio-Techne's Background

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Financial Milestones: Bio-Techne's Journey

Revenue Growth: Bio-Techne displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.59%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Profitability Metrics: Unlocking Value

• Gross Margin: The company maintains a high gross margin of 66.43%, indicating strong cost management and profitability compared to its peers.

• Earnings per Share (EPS): Bio-Techne's EPS reflects a decline, falling below the industry average with a current EPS of 0.26.

Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.

Market Valuation:

• Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 71.2 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.

• Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.37 as compared to the industry average, the stock might be considered overvalued based on sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): A high EV/EBITDA ratio of 38.73 reflects market recognition of Bio-Techne's value, positioning it as more highly valued compared to industry peers.

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Uncovering the Importance of Insider Activity

While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.

In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.

When a company insider makes a new purchase, that is an indication that they expect the stock to rise.

Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.

Transaction Codes Worth Your Attention

Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Bio-Techne's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.